Ophthotech, Novartis Enter Into Ex-US Licensing And Commercialization Agreement

Ocular Surgery News

Ophthotech Corp. has entered into an ex-U.S. licensing and commercialization agreement with Novartis Pharmaceuticals for Fovista, an anti-PDGF in development for the treatment of wet age-related macular degeneration, according to a press release.
  • <<
  • >>

Comments